MoonLake Immunotherapeutics (MLTX)
40.85
+0.89
(+2.23%)
USD |
NASDAQ |
May 24, 16:00
40.86
+0.01
(+0.02%)
After-Hours: 20:00
MoonLake Immunotherapeutics Cash from Financing (Quarterly): 50.98M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 50.98M |
| December 31, 2023 | 28.42M |
| September 30, 2023 | 0.00 |
| June 30, 2023 | 451.29M |
| March 31, 2023 | 0.00 |
| Date | Value |
|---|---|
| December 31, 2022 | 0.0038M |
| September 30, 2022 | 0.00 |
| June 30, 2022 | 104.69M |
| March 31, 2022 | 15.00M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
--
Minimum
Sep 2022
451.29M
Maximum
Jun 2023
72.26M
Average
15.00M
Median
Mar 2022
Cash from Financing (Quarterly) Benchmarks
| Qiagen NV | -292.09M |
| LENZ Therapeutics Inc | 171.27M |
| AC Immune SA | -0.7872M |
| CRISPR Therapeutics AG | 305.93M |
| Addex Therapeutics Ltd | -0.1643M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -14.95M |
| Cash from Investing (Quarterly) | -28.80M |
| Free Cash Flow | -48.91M |
| Free Cash Flow Per Share (Quarterly) | -0.242 |
| Free Cash Flow Yield | -2.18% |